{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:40:37Z","timestamp":1791520837047,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Hydralazine, doxazosin, and verapamil are currently recommended by the Endocrine Society as acceptable bridging treatment in those in whom full cessation of antihypertensive medication is infeasible during screening for primary aldosteronism (PA). This is under the assumption that they cause minimal to no effect on the aldosterone-to-renin ratio, the most widely used screening test for PA. However, limited evidence is available regarding the effects of these particular drugs on said ratio.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the present study, we retrospectively assessed the changes in aldosterone, renin, and aldosterone-to-renin values in essential hypertensive participants before and after treatment with either hydralazine (<jats:italic>n<\/jats:italic>\u2009=\u200926) or doxazosin (<jats:italic>n<\/jats:italic>\u2009=\u200920) or verapamil (<jats:italic>n<\/jats:italic>\u2009=\u200915). All samples were taken under highly standardized conditions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Hydralazine resulted in a borderline significant rise in active plasma renin concentration (19 vs 25 mIU\/L, <jats:italic>p<\/jats:italic>\u2009=\u20090.067) and a significant fall in the aldosterone-to-renin ratio (38 vs 24, <jats:italic>p<\/jats:italic>\u2009=\u20090.017). Doxazosin caused declines in both plasma aldosterone concentration (470 vs 330\u00a0pmol\/L, <jats:italic>p<\/jats:italic>\u2009=\u20090.028) and the aldosterone-to-renin ratio (30 vs 20, <jats:italic>p<\/jats:italic>\u2009=\u20090.020). With respect to verapamil, we found no statistically significant effect on any of these outcome variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We conclude that the assumption that these drugs can be used with little consequence to the aldosterone-to-renin cannot be substantiated. While it is possible that they are indeed the best option when full antihypertensive drug cessation is infeasible, the potential effects of these drugs must still be taken into account when interpreting the aldosterone-to-renin ratio.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-021-07262-3","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T08:03:02Z","timestamp":1631520182000},"page":"283-289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof"],"prefix":"10.1007","volume":"37","author":[{"given":"Gregory P.","family":"Veldhuizen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan M.","family":"Alnazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4949-5812","authenticated-orcid":false,"given":"Peter W.","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham A.","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"issue":"5","key":"7262_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916. https:\/\/doi.org\/10.1210\/jc.2015-4061.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7262_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/jch.14173","volume":"23","author":"RM Alnazer","year":"2021","unstructured":"Alnazer RM, Veldhuizen GP, Kroon AA, de Leeuw PW. The effect of medication on the aldosterone-to-renin ratio. A critical review of the literature. J Clin Hypertens (Greenwich). 2021;23(2):208\u201314. https:\/\/doi.org\/10.1111\/jch.14173.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"7262_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.hyp.0000038478.59760.41","volume":"40","author":"P Mulatero","year":"2002","unstructured":"Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40(6):897\u2013902. https:\/\/doi.org\/10.1161\/01.hyp.0000038478.59760.41.","journal-title":"Hypertension"},{"issue":"1","key":"7262_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/clpt.1987.107","volume":"42","author":"RL Byyny","year":"1987","unstructured":"Byyny RL, Nies AS, LoVerde ME, Mitchell WD. A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension. Clin Pharmacol Ther. 1987;42(1):50\u20137. https:\/\/doi.org\/10.1038\/clpt.1987.107.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"7262_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/0002-9343(87)90160-4","volume":"82","author":"FH Leenen","year":"1987","unstructured":"Leenen FH, Smith DL, Farkas RM, Reeves RA, Marquez-Julio A. Vasodilators and regression of left ventricular hypertrophy Hydralazine versus prazosin in hypertensive humans. Am J Med. 1987;82(5):969\u201378. https:\/\/doi.org\/10.1016\/0002-9343(87)90160-4.","journal-title":"Am J Med."},{"issue":"3","key":"7262_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1148\/radiology.146.3.6338555","volume":"146","author":"AS Gomes","year":"1983","unstructured":"Gomes AS, Sinaiko AR, Tobian L, Cohn JN, Formanek G, Amplatz K. Hydralazine and the tourniquet test in renal vein renin sampling: a comparison. Radiology. 1983;146(3):657\u201361. https:\/\/doi.org\/10.1148\/radiology.146.3.6338555.","journal-title":"Radiology"},{"issue":"3","key":"7262_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1148\/radiology.153.3.6387785","volume":"153","author":"AS Gomes","year":"1984","unstructured":"Gomes AS, Sinaiko AR, Tobian L, Cohn JN, Formanek AG, Roe DJ, et al. Renal vein renin sampling in essential hypertension using hydralazine and the tourniquet test. Radiology. 1984;153(3):619\u201323. https:\/\/doi.org\/10.1148\/radiology.153.3.6387785.","journal-title":"Radiology"},{"issue":"1","key":"7262_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0002-9149(84)90693-3","volume":"53","author":"GS Thind","year":"1984","unstructured":"Thind GS, Montojo PM, Johnson A, Amin E. Enhancement of renal venous renin ratios by intravenous hydralazine in renovascular hypertension. Am J Cardiol. 1984;53(1):109\u201315. https:\/\/doi.org\/10.1016\/0002-9149(84)90693-3.","journal-title":"Am J Cardiol"},{"issue":"5","key":"7262_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archinte.1968.00040010387001","volume":"122","author":"H Ueda","year":"1968","unstructured":"Ueda H, Yagi S, Kaneko Y. Hydralazine and plasma renin activity. Arch Intern Med. 1968;122(5):387\u201391.","journal-title":"Arch Intern Med"},{"key":"7262_CR10","doi-asserted-by":"publisher","unstructured":"Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane Database Syst Rev. 2011(11):CD004934. https:\/\/doi.org\/10.1002\/14651858.CD004934.pub4.","DOI":"10.1002\/14651858.CD004934.pub4"},{"issue":"5","key":"7262_CR11","first-page":"465","volume":"34","author":"MA Riddiough","year":"1977","unstructured":"Riddiough MA. Preventing, detecting and managing adverse reactions of antihypertensive agents in the ambulant patient with essential hypertension. Am J Hosp Pharm. 1977;34(5):465\u201379.","journal-title":"Am J Hosp Pharm"},{"issue":"1","key":"7262_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1074248415587969","volume":"21","author":"MN McComb","year":"2016","unstructured":"McComb MN, Chao JY, Ng TM. Direct vasodilators and sympatholytic agents. J Cardiovasc Pharmacol Ther. 2016;21(1):3\u201319. https:\/\/doi.org\/10.1177\/1074248415587969.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"7262_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2165\/00003088-199834060-00003","volume":"34","author":"R Kirsten","year":"1998","unstructured":"Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part I Clin Pharmacokinet. 1998;34(6):457\u201382. https:\/\/doi.org\/10.2165\/00003088-199834060-00003.","journal-title":"Part I Clin Pharmacokinet"},{"issue":"1","key":"7262_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.1976.56.1.1","volume":"56","author":"JO Davis","year":"1976","unstructured":"Davis JO, Freeman RH. Mechanisms regulating renin release. Physiol Rev. 1976;56(1):1\u201356. https:\/\/doi.org\/10.1152\/physrev.1976.56.1.1.","journal-title":"Physiol Rev"},{"key":"7262_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.pa.22.040182.001123","volume":"22","author":"J Torretti","year":"1982","unstructured":"Torretti J. Sympathetic control of renin release. Annu Rev Pharmacol Toxicol. 1982;22:167\u201392. https:\/\/doi.org\/10.1146\/annurev.pa.22.040182.001123.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"7262_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00004872-198502000-00007","volume":"3","author":"MD Guazzi","year":"1985","unstructured":"Guazzi MD, Barbier P, Loaldi A, Montorsi P, Polese A, Tosi E, et al. Intrarenal beta-receptor and renal baroreceptor interaction in the control of the renin response to transient reduction of the renal perfusion pressure in man. J Hypertens. 1985;3(1):39\u201345. https:\/\/doi.org\/10.1097\/00004872-198502000-00007.","journal-title":"J Hypertens"},{"issue":"5","key":"7262_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/01.cir.56.5.691","volume":"56","author":"AS Zanchetti","year":"1977","unstructured":"Zanchetti AS. Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation. 1977;56(5):691\u20138. https:\/\/doi.org\/10.1161\/01.cir.56.5.691.","journal-title":"Circulation"},{"issue":"1","key":"7262_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/00005344-198707000-00013","volume":"10","author":"H Shionoiri","year":"1987","unstructured":"Shionoiri H, Yasuda G, Yoshimura H, Umemura S, Miyajima E, Miyakawa T, et al. Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol. 1987;10(1):90\u20135. https:\/\/doi.org\/10.1097\/00005344-198707000-00013.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"7262_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3109\/10641969409078021","volume":"16","author":"GS Stokes","year":"1994","unstructured":"Stokes GS, Johnston HJ, Okoro EO, Boutagy J, Monaghan JC, Marwood JF. Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients. Clin Exp Hypertens. 1994;16(6):709\u201327. https:\/\/doi.org\/10.3109\/10641969409078021.","journal-title":"Clin Exp Hypertens"},{"issue":"2","key":"7262_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0002-9149(91)90438-Q","volume":"67","author":"MC Oliveros-Palacios","year":"1991","unstructured":"Oliveros-Palacios MC, Godoy-Godoy N, Colina-Chourio JA. Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein. Am J Cardiol. 1991;67(2):157\u201361.","journal-title":"Am J Cardiol"},{"issue":"6 Pt 2","key":"7262_CR21","first-page":"III210","volume":"9","author":"PW De Leeuw","year":"1987","unstructured":"De Leeuw PW, Van Es PN, De Bos R, Birkenh\u00e4ger WH. Role of alpha 1 and alpha 2 adrenergic receptors in the human hypertensive kidney. Hypertension. 1987;9(6 Pt 2):III210-2.","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"7262_CR22","doi-asserted-by":"publisher","first-page":"41S","DOI":"10.1111\/j.1365-2125.1986.tb02852.x","volume":"21","author":"PW de Leeuw","year":"1986","unstructured":"de Leeuw PW, van Es PN, De Bos R, Birkenhager WH. Acute renal effects of doxazosin in man. Br J Clin Pharmacol. 1986;21(Suppl 1):41S-S43. https:\/\/doi.org\/10.1111\/j.1365-2125.1986.tb02852.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"7262_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2362.1985.tb00163.x","volume":"15","author":"PW de Leeuw","year":"1985","unstructured":"de Leeuw PW, de Bos R, van Es PN, Birkenhager WH. Effect of sympathetic stimulation and intrarenal alpha-blockade on the secretion of renin by the human kidney. Eur J Clin Invest. 1985;15(4):166\u201370. https:\/\/doi.org\/10.1111\/j.1365-2362.1985.tb00163.x.","journal-title":"Eur J Clin Invest"},{"issue":"Suppl 1","key":"7262_CR24","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1007\/BF01409207","volume":"39","author":"B Fagher","year":"1990","unstructured":"Fagher B, Henningsen N, Hulthen L, Katzman P, Thulin T. Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. A double-blind, randomized study. Eur J Clin Pharmacol. 1990;39(Suppl 1):S41-3. https:\/\/doi.org\/10.1007\/BF01409207.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6657","key":"7262_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1136\/bmj.297.6657.1155","volume":"297","author":"JK Cruickshank","year":"1988","unstructured":"Cruickshank JK, Anderson NM, Wadsworth J, Young SM, Jepson E. Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. BMJ. 1988;297(6657):1155\u20139. https:\/\/doi.org\/10.1136\/bmj.297.6657.1155.","journal-title":"BMJ"},{"issue":"5","key":"7262_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2125.1988.tb03351.x","volume":"25","author":"MC Chellingsworth","year":"1988","unstructured":"Chellingsworth MC, Kendall MJ. Effects of nifedipine, verapamil and diltiazem on renal function. Br J Clin Pharmacol. 1988;25(5):599\u2013602. https:\/\/doi.org\/10.1111\/j.1365-2125.1988.tb03351.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"7262_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/clpt.1987.185","volume":"42","author":"P Stadler","year":"1987","unstructured":"Stadler P, Leonardi L, Riesen W, Ziegler W, Marone C, Beretta-Piccoli C. Cardiovascular effects of verapamil in essential hypertension. Clin Pharmacol Ther. 1987;42(5):485\u201392. https:\/\/doi.org\/10.1038\/clpt.1987.185.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"7262_CR28","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/s0735-1097(86)80357-6","volume":"7","author":"E Agabiti-Rosei","year":"1986","unstructured":"Agabiti-Rosei E, Muiesan ML, Romanelli G, Castellano M, Beschi M, Corea L, et al. Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine. J Am Coll Cardiol. 1986;7(4):916\u201324. https:\/\/doi.org\/10.1016\/s0735-1097(86)80357-6.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"7262_CR29","doi-asserted-by":"publisher","first-page":"44D","DOI":"10.1016\/0002-9149(86)90805-2","volume":"57","author":"G Muiesan","year":"1986","unstructured":"Muiesan G, Agabiti-Rosei E, Romanelli G, Muiesan ML, Castellano M, Beschi M. Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol. 1986;57(7):44D-D49. https:\/\/doi.org\/10.1016\/0002-9149(86)90805-2.","journal-title":"Am J Cardiol"},{"issue":"3","key":"7262_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF00544077","volume":"29","author":"SS Sorensen","year":"1985","unstructured":"Sorensen SS, Thomsen OO, Danielsen H, Pedersen EB. Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension. Eur J Clin Pharmacol. 1985;29(3):257\u201361. https:\/\/doi.org\/10.1007\/BF00544077.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 3","key":"7262_CR31","first-page":"S325","volume":"4","author":"G Muiesan","year":"1982","unstructured":"Muiesan G, Agabiti-Rosei E, Castellano M, Alicandri CL, Corea L, Fariello R, et al. Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension. J Cardiovasc Pharmacol. 1982;4(Suppl 3):S325\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"7262_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1291\/hypres.23.537","volume":"23","author":"N Sun","year":"2000","unstructured":"Sun N, Hong T, Zhang R, Yang X. The effects of verapamil SR and bisoprolol on reducing the sympathetic nervous system\u2019s activity. Hypertens Res. 2000;23(5):537\u201340. https:\/\/doi.org\/10.1291\/hypres.23.537.","journal-title":"Hypertens Res"},{"issue":"4","key":"7262_CR33","first-page":"31","volume":"15","author":"S Zacharieva","year":"1989","unstructured":"Zacharieva S, Koev D, Matrozov P, Tcharaktchiev D, Stoeva I, Andonova K. Effect of verapamil on renin-angiotensin-aldosterone system, urinary 6-keto prostaglandin F1 alpha and aldosterone response to metoclopramide in normal man. Acta Physiol Pharmacol Bulg. 1989;15(4):31\u20136.","journal-title":"Acta Physiol Pharmacol Bulg"},{"issue":"5","key":"7262_CR34","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/0002-9149(82)90438-6","volume":"50","author":"WH Frishman","year":"1982","unstructured":"Frishman WH, Klein NA, Klein P, Strom JA, Tawil R, Strair R, et al. Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial. Am J Cardiol. 1982;50(5):1164\u201372. https:\/\/doi.org\/10.1016\/0002-9149(82)90438-6.","journal-title":"Am J Cardiol."},{"issue":"12","key":"7262_CR35","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1177\/009127009203201211","volume":"32","author":"JW Buckley","year":"1992","unstructured":"Buckley JW, Hedner T, Masotto C, Posvar E, Negro-Villar A, Cubeddu LX. Comparative effects of verapamil and volume overload on atrial natriuretic factors and the renin-angiotensin aldosterone-vasopressin system. J Clin Pharmacol. 1992;32(12):1120\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"7262_CR36","doi-asserted-by":"publisher","first-page":"E388","DOI":"10.1152\/ajpendo.1977.232.4.E388","volume":"232","author":"TA Kotchen","year":"1977","unstructured":"Kotchen TA, Galla JH, Luke RG. Effects of calcium on renin and aldosterone in the rat. Am J Physiol. 1977;232(4):E388\u201393. https:\/\/doi.org\/10.1152\/ajpendo.1977.232.4.E388.","journal-title":"Am J Physiol"},{"issue":"5","key":"7262_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/BF03348177","volume":"10","author":"G Opocher","year":"1987","unstructured":"Opocher G, Rocco S, Murgia A, Mantero F. Effect of verapamil on aldosterone secretion in primary aldosteronism. J Endocrinol Invest. 1987;10(5):491\u20134. https:\/\/doi.org\/10.1007\/BF03348177.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"7262_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF00548759","volume":"26","author":"D Magometschnigg","year":"1984","unstructured":"Magometschnigg D, Hortnagl H, Rameis H. Diltiazem and verapamil: functional antagonism of exogenous noradrenaline and angiotensin II in man. Eur J Clin Pharmacol. 1984;26(3):303\u20137. https:\/\/doi.org\/10.1007\/BF00548759.","journal-title":"Eur J Clin Pharmacol"},{"key":"7262_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.0954-6820.1984.tb08686.x","volume":"681","author":"PW de Leeuw","year":"1984","unstructured":"de Leeuw PW, Birkenhager WH. Effects of verapamil in hypertensive patients. Acta Med Scand Suppl. 1984;681:125\u20138. https:\/\/doi.org\/10.1111\/j.0954-6820.1984.tb08686.x.","journal-title":"Acta Med Scand Suppl"},{"issue":"2","key":"7262_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1210\/jcem-57-2-339","volume":"57","author":"GP Guthrie Jr","year":"1983","unstructured":"Guthrie GP Jr, McAllister RG Jr, Kotchen TA. Effects of intravenous and oral verapamil upon pressor and adrenal steroidogenic responses in normal man. J Clin Endocrinol Metab. 1983;57(2):339\u201343. https:\/\/doi.org\/10.1210\/jcem-57-2-339.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7262_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/jch.14117","volume":"23","author":"GP Veldhuizen","year":"2021","unstructured":"Veldhuizen GP, Alnazer RM, Kroon AA, de Leeuw PW. Confounders of the aldosterone-to-renin ratio when used as a screening test in hypertensive patients: a critical analysis of the literature. J Clin Hypertens (Greenwich). 2021;23(2):201\u20137. https:\/\/doi.org\/10.1111\/jch.14117.","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07262-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07262-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07262-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T16:06:39Z","timestamp":1678809999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07262-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["7262"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07262-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"6 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies described in this paper were approved by the local Medical Ethical Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individuals who participated in the studies described in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"By their consent to participate in the studies, patients also consented to the (anonymous) publication of the study results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}